{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T11:07:13Z","timestamp":1761563233089,"version":"build-2065373602"},"reference-count":19,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100007747","name":"The University of Utah","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007747","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cardiovascular Revascularization Medicine"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1016\/j.carrev.2021.10.014","type":"journal-article","created":{"date-parts":[[2021,11,5]],"date-time":"2021-11-05T18:24:12Z","timestamp":1636136652000},"page":"61-62","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Frailty and TAVR\u2014Is This the Hard-to-Define Glass Ceiling?"],"prefix":"10.1016","volume":"34","author":[{"given":"Robert C.","family":"Sturm","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan","family":"Harrison","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anwar","family":"Tandar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.carrev.2021.10.014_bb0005","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1007\/s12471-020-01468-0","article-title":"The history of transcatheter aortic valve implantation: the role and contribution of an early believer and adopter, the Netherlands","volume":"28","author":"de Jaegere","year":"2020","journal-title":"Neth Heart J"},{"key":"10.1016\/j.carrev.2021.10.014_bb0010","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1161\/CIRCRESAHA.114.302292","article-title":"Evolution of transcatheter aortic valve replacement","volume":"114","author":"Bourantas","year":"2014","journal-title":"Circ Res"},{"key":"10.1016\/j.carrev.2021.10.014_bb0015","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1136\/heart.85.2.196","article-title":"Variability in treatment advice for elderly patients with aortic stenosis: a nationwide survey in the Netherlands","volume":"85","author":"Bouma","year":"2001","journal-title":"Heart"},{"key":"10.1016\/j.carrev.2021.10.014_bb0020","first-page":"374","article-title":"Which elderly patients with severe aortic stenosis benefit from surgical treatment? An aid to clinical decision making","volume":"13","author":"Bouma","year":"2004","journal-title":"J Heart Valve Dis"},{"key":"10.1016\/j.carrev.2021.10.014_bb0025","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1136\/hrt.82.2.143","article-title":"To operate or not on elderly patients with aortic stenosis: the decision and its consequences","volume":"82","author":"Bouma","year":"1999","journal-title":"Heart"},{"key":"10.1016\/j.carrev.2021.10.014_bb0030","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1161\/CIRCOUTCOMES.109.848259","article-title":"Evaluation of patients with severe symptomatic aortic stenosis who do not undergo aortic valve replacement: the potential role of subjectively overestimated operative risk","volume":"2","author":"Bach","year":"2009","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"10.1016\/j.carrev.2021.10.014_bb0035","doi-asserted-by":"crossref","first-page":"3290","DOI":"10.1161\/CIRCULATIONAHA.104.495903","article-title":"Outcome of 622 adults with asymptomatic, hemodynamically significant aortic stenosis during prolonged follow-up","volume":"111","author":"Pellikka","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.carrev.2021.10.014_bb0040","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/jocs.14336","article-title":"\"The changing paradigm\": TAVR for low-risk patients approved by the FDA","volume":"35","author":"Gomez","year":"2020","journal-title":"J Card Surg"},{"key":"10.1016\/j.carrev.2021.10.014_bb0045","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.athoracsur.2020.09.002","article-title":"STS-ACC TVT registry of transcatheter aortic valve replacement","volume":"111","author":"Carroll","year":"2021","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.carrev.2021.10.014_bb0050","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1056\/NEJMoa1103510","article-title":"Transcatheter versus surgical aortic-valve replacement in high-risk patients","volume":"364","author":"Smith","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.carrev.2021.10.014_bb0055","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.hlc.2016.01.005","article-title":"Transcatheter versus surgical aortic valve replacement in high-risk patients: a propensity-score matched analysis","volume":"25","author":"Zweng","year":"2016","journal-title":"Heart Lung Circ"},{"key":"10.1016\/j.carrev.2021.10.014_bb0060","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1056\/NEJMoa1008232","article-title":"Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery","volume":"363","author":"Leon","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.carrev.2021.10.014_bb0065","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1161\/CIRCULATIONAHA.111.040022","article-title":"Health-related quality of life after transcatheter aortic valve replacement in inoperable patients with severe aortic stenosis","volume":"124","author":"Reynolds","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.carrev.2021.10.014_bb0070","doi-asserted-by":"crossref","first-page":"2682","DOI":"10.1161\/CIRCULATIONAHA.113.007477","article-title":"Predictors of poor outcomes after transcatheter aortic valve replacement: results from the PARTNER (Placement of aortic transcatheter Valve) trial","volume":"129","author":"Arnold","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.carrev.2021.10.014_bb0075","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/j.jacc.2017.06.024","article-title":"Frailty in older adults undergoing aortic valve replacement: the FRAILTY-AVR study","volume":"70","author":"Afilalo","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.carrev.2021.10.014_bb0080","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1016\/j.jcin.2020.01.238","article-title":"Frailty and bleeding in older adults undergoing TAVR or SAVR: insights from the FRAILTY-AVR study","volume":"13","author":"Afilalo","year":"2020","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.carrev.2021.10.014_bb0085","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/j.jcin.2019.02.049","article-title":"Habitual physical activity in older adults undergoing TAVR: insights from the FRAILTY-AVR study","volume":"12","author":"Sathananthan","year":"2019","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.carrev.2021.10.014_bb0090","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.carrev.2021.02.004","article-title":"Frailty predicts adverse outcomes in older patients undergoing transcatheter aortic valve replacement (TAVR). From the National Inpatient Sample","volume":"34","author":"Abugroun","year":"2022","journal-title":"Cardiovasc Revasc Med"},{"key":"10.1016\/j.carrev.2021.10.014_bb0095","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1016\/j.carrev.2020.05.044","article-title":"Very early changes in quality of life after transcatheter aortic valve replacement: results from the 3M TAVR trial","volume":"21","author":"Lauck","year":"2020","journal-title":"Cardiovasc Revasc Med"}],"container-title":["Cardiovascular Revascularization Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1553838921007193?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1553838921007193?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T10:21:30Z","timestamp":1761560490000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1553838921007193"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":19,"alternative-id":["S1553838921007193"],"URL":"https:\/\/doi.org\/10.1016\/j.carrev.2021.10.014","relation":{},"ISSN":["1553-8389"],"issn-type":[{"type":"print","value":"1553-8389"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Frailty and TAVR\u2014Is This the Hard-to-Define Glass Ceiling?","name":"articletitle","label":"Article Title"},{"value":"Cardiovascular Revascularization Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.carrev.2021.10.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}